Securitizing the Future of Orphan Disease Therapies
A simulation study explores the use of securitization as a novel financial mechanism to fund expensive cell and gene therapies for orphan diseases. Published in *Gene Therapy*, the research models how future revenue streams from these advanced treatments could be bundled into financial securities, offering a potential solution to the critical challenge of sustainable payment models in high-cost, low-volume therapeutic areas. This approach aims to address the acute care funding gap that often hinders patient access to life-saving interventions for rare conditions.
Study Significance: For emergency medicine and acute care specialists, this research highlights the evolving financial landscape surrounding advanced therapies. Understanding these novel payment models is crucial, as they directly influence which cutting-edge treatments become available for managing critical conditions and rare disease emergencies in the clinical setting. The findings suggest that innovative financing could accelerate the integration of specialized gene and cell therapies into emergency and critical care protocols, potentially altering long-term management strategies for complex patients.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
